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Over one billion people worldwide are predicted to harbor Toxoplasma infection frequently
with unknown lifelong health consequences. Toxoplasmosis is an important cause of
foodborne, inflammatory illnesses, as well as congenital abnormalities. Ubiquitous
Toxoplasma has a unique tropism for central nervous system with a mind-bugging effect
and is transmitted sexually through semen. Currently available therapies are ineffective for
persistent chronic disease and congenital toxoplasmosis or have severe side effects which
may result in life-threatening complications. There is an urgent need for safe and effective
therapies to eliminate or treat this cosmopolitan infectious and inflammatory disease.
This investigation discusses pathogenesis of maternal and congenital toxoplasmosis, the
currently available therapies in practice, and the experimental therapeutic modalities for
promising future trials.
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INTRODUCTION
Over one billion people worldwide are predicted to harbor
Toxoplasma infection frequently with unknown lifelong health
consequences. Toxoplasmosis is one of the most important food-
borne inflammatory illnesses, as well as congenital abnormalities
(Hoffmann et al., 2012). Toxoplasma is classified as “Category B
pathogen”which once infected, the organisms dwell in organs such
as muscles and brain in cyst forms for the life of the patient/host
to become reactivated. The organisms have a sexual stage in cat’s
intestinal epithelial cells which form resistant oocysts passed in
feces and matured in dirt (Figure 1). Humans and other animals
develop systemic infection in asexual form by ingestion of contam-
inated vegetable, fruits, water, or consumption of infected milk and
undercooked sea food, poultry, and livestock. Tachyzoites infect
nucleated host cells and utilize monocytes, macrophages, and den-
dritic cells as“Trojan Horse”(1) to escape the host immune defense
(Elsheikha and Khan, 2010), (2) to bypass the blood–brain barrier
(Bierly et al., 2008) and the placenta barricade, and (3) to spread
and form systemic disease. Toxoplasma infests particularly rural
and impoverish communities of women, African American, His-
panics, and Native Americans as a “frequently ignored disease of
poverty” (Hotez, 2008). Toxoplasmosis is considered as the sec-
ond major cause of foodborne death in the United States (Scallan
et al., 2011). The Toxoplasma annual cost of illnesses is about $3
billion and the quality-adjusted life loss is equal to 11,000 years
in the United States (Hoffmann et al., 2012). Toxoplasmosis in
immune-intact individuals is generally symptomless and unde-
tected or appears like flu syndrome and malaise. However, it
can cause severe pathological consequences in immunocompro-
mised patients, fetuses, and neonates and lead to demise and death
(Dubey and Jones, 2008).
MATERNAL CONGENITAL TOXOPLASMOSIS
The importance of maternal and congenital transmission has long
been recognized since 1939; when a neonate from New York
developed toxoplasmosis (Wolf et al., 1939; Jones et al., 2001). Dur-
ing progression of pregnancy, maternal immune system confronts
a dual predicament: the growing embryo, and the environmental
toxins and pathogens threatening mom and fetus. In fact, suc-
cessful pregnancy involves an elegant equilibrium in organizing
the immune system at the fetal-maternal and uteri milieu result-
ing in tolerance (TH2) of the fetus (Norwitz et al., 2001; Muzzio
et al., 2014) and defense (TH1) against the pathogenic agents.
Women who have acute or reactivated toxoplasmosis during preg-
nancy can transplacentally transmit organisms to their fetus. As,
tachyzoites bypass the placental blood barrier and invade the fetal
organs to propagate and compromise the embryonic develop-
mental process. About 50–80% of child-bearing Brazilian women
and 50% of children have anti-Toxoplasma antibodies. Also, 5–23
neonates are found to be infected per 10,000 in Brazil (Dubey et al.,
2012).
Congenital toxoplasmosis can manifest with severe compli-
cations, such as miscarriage, fetal developmental retardation,
encephalitis, neurological, mental illnesses, visual, and auditory
inflammatory disorders, cardiovascular abnormalities, and pains
(Dunn et al., 1999; Gilbert and Gras, 2003; Gras et al., 2005;
McLeod et al., 2006; Remington et al., 2006; Oz and Tobin, 2012).
The severity of complications relies on the gestation period, as the
early infection shows more severe outcomes (Dunn et al., 1999;
Remington et al., 2006). While, fetuses infected in late gestation
are born normal, may develop central nervous system (CNS)
symptoms and retinochoroiditis later in life. Also, the new lesions
may occur in untreated as well as treated children (Dunn et al.,
1999).
A predominant source of infection in North America is con-
taminated food and water with oocysts passed in the cat’s (definite
host) feces (Boyer et al., 2011). Sera and surveys from 76 moms
with congenital infected newborns were collected from four differ-
ent epidemic areas and investigated by the National collaborative
Chicago-based congenital toxoplasmosis. The data revealed 78%
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FIGURE 1 | Multiple sources of ubiquitousToxoplasma for maternal congenital transmission.
of the moms acquired primary infection from oocysts form, while
only 49% had direct contact with house cats. Hence, extensive edu-
cational hygienic programs, effective cats’ infection prevention,
and vaccination plans, along with serological testing of pregnant
women and newborns, followed by the treatments are needed to
prevent maternal congenital toxoplasmosis (Boyer et al., 2011).
MATERNAL REACTIVATION AND CONGENITAL
TOXOPLASMOSIS
Toxoplasmosis reactivation is a major concern in pregnant,
immunodeficient, blood transfusion, bone marrow, and organ
transplant patients, when the protective cyst’s wall ruptures
and organisms reach the lymphatic and blood cells to acti-
vate and propagate the infection. Maternal congenital toxo-
plasmosis is instigated by the transplacental transmission of
organisms in maternal infection (Buxton et al., 1991), as Tox-
oplasma organisms alter balance in immune milieu leading to
inflammatory response. A low number of Toxoplasma organisms
can induce an extensive inflammatory and immune reaction as
shown in the murine model of fetomaternal toxoplasmosis (Oz
and Tobin, 2012). Therefore, taming exaggerated inflammatory
response in fetal–maternal toxoplasmosis is necessary to pre-
vent severe tissue destruction and fatality during the pathogenic
clearance.
According to Massachusetts Department of Health, about 1 case
of congenital toxoplasmosis occurs for every 10,000 live births. It
is estimated that from 4,000,000 live births each year in the United
States, 400 have acquired congenital toxoplasmosis (Mead et al.,
1999). This rate is extensively higher for other developing coun-
tries. For instance, retrospective trials from Argentina (2000–2011)
reviled 18% (2206/12035) prevalence rate of anti-Toxoplasma
antibody in pregnant women. Thirty eight per 10,000 of these
moms had developed acute infection and 5.8% transplacentally
infected their neonates (Carral et al., 2013).
TOXOPLASMA MIND-BUGGING SEXUAL ATTRACTION AND
MENTAL DISORDERS
Recent investigations reveal that Toxoplasma provokes a brain and
mind alteration with sexual arousal in rats seeking cat, while
uninfected normal rats fear and avoid predator’s urine odor with
an immediate, innate survival defensive behavior (House et al.,
2011; Knight, 2013). Therefore, the brain impaired and fearless
infected rodents are eaten up by feline to fulfill the organism’s
sexual propagation in definitive host “cat”. Toxoplasma manipu-
lates the limbic brain neurons responsible for instinct defensive
response and augments activity in adjacent limbic regions of
sexual desire when exposed to cat’s urine odor (House et al.,
2011).
Toxoplasmosis is a sexually communicable disease as organisms
are transmitted by contaminated semen during natural mating.
Also, artificial insemination with contaminated semen can infect
animals with vertical transmission with 80% embryonic disrup-
tion (Arantes et al., 2009; Lopes et al., 2013; Wanderley et al.,
2013). Indeed, there exists a potential sexual transmission route
with infected semen during mating as well as artificial insemi-
nation with subsequent vertical transmission to the progeny in
humans.
Toxoplasma has strong tropism for the CNS with adverse
affect in the brain neuro-structural development and patho-
logical as well as psycho-behavioral impairment and mental
challenges (Bachmann et al., 2005; Brown et al., 2005; Wang
et al., 2006). Maternal Toxoplasma infection has been related
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with risk for schizophrenic events and autism with over 40 sup-
porting investigations for the incidence of Toxoplasma infection
among these patients (Flegr, 2013). Toxoplasma infection may
evolve brain dopamine dysregulation (Torrey et al., 2007; Fekadu
et al., 2010). Longitudinal and cross-sectional trials in seropos-
itive females with chronic toxoplasmosis have shown high risk
of self-harm, accidents and non-fatal suicidal aggression than
in seronegative individuals (Pedersen et al., 2012; Zhang et al.,
2012).
Pregnant women with latent infection have a higher risk of
infants with genetic or developmental disorders such as premature
and postnatal slow motor development due to infection provoked
immunosuppression in moms. Some of these defects are related
to malnutrition caused by diarrhea and gut disorders or directly
congenital toxoplasmosis induced cognitive and developmental
deficits (Kankova et al., 2012).
AUTOIMMUNE DISEASE AND TOXOPLASMOSIS
Ubiquitous Toxoplasma infection is indicated to provoke series
of chronic inflammatory and autoimmune disorders. Immuno-
suppressants and monoclonal antibodies such as anti-TNF which
are widely used in healthcare for the treatment of autoim-
mune diseases, and organ transplantation may result in acute
toxoplasmosis in these patients. However, the nature of this
interaction and mechanism between the development of acute
toxoplasmosis and immunosuppressant therapies are still being
investigated. In a clinical trial, sera of 1514 patients with 11
different autoimmune diseases from health centers in Europe
and Latin America and 437 matched controls examined for
the prevalence of anti-Toxoplasma antibodies, IgG and IgM
and auto-antibodies (Shapira et al., 2012). Fourty-two percent
of patients had anti-Toxoplasma antibody IgG, versus 29% of
those without autoimmune complications (p < 0.0001). Anti-
Toxoplasma antibody IgG was associated with anti-phospholipid
syndrome, autoimmune thyroid diseases, systemic sclerosis, and
rheumatoid arthritis (p < 0.0001). Anti-Toxoplasma antibody
IgM was more prevalent in patients with anti-phospholipid
syndrome (p < 0.01), systemic sclerosis (p < 0.05) and
inflammatory bowel disease (IBD; p < 0.05) than in controls.
These findings strongly support that Toxoplasma may con-
tribute to the autoimmune disease pathogenesis (Shapira et al.,
2012).
Crohn’s disease and ulcerative colitis (IBD) are considered
as autoimmune response of a leaky gut to microbiota, when
toxins, like Gram-negative lipopolysaccharide (LPS), bypassing
the inflamed epithelia by underlying dysregulated oral toler-
ance (Brandtzaeg, 2001; Oz et al., 2009, 2013). The use of
biological blockers, like anti-TNF antibodies, and immunosup-
pressives in IBD patients increases the risk of opportunistic
diseases (Oz and Ebersole, 2009). Crohn’s patients are prone
to intestinal abscess formation including Toxoplasma infection
(Epple, 2009). Dams infected with Toxoplasma develop severe
colonic inflammatory response with significant shortening in
colonic length, infiltration of lymphocytes, and macrophages and
microabscess formations in the cryptic microstructures resem-
bling Crohn’s pathogenesis (Oz and Tobin, 2012, 2014; Oz,
2014). Similar to colitis, Toxoplasma-induced ileitis elevates
precarious gut microbial, LPS and lipopeptide contents (Erridge
et al., 2010). Anti-Toxoplasma titer has been detected signifi-
cantly higher in IBD patients than healthy controls; supporting
the notion that toxoplasmosis to trigger IBD and specifically
Crohn’s disease pathogenesis in patients (Lidar et al., 2009).
Toxoplasma infection causes an excessive Th1 systemic inflam-
mation and promotes pro-atherogenesis (Portugal et al., 2009;
Lige et al., 2013). Therefore, inflammatory response may act
as a dual-edged sword. While, necessary for the host defense
and recovery against pathogens, unleashed exaggerated chronic
inflammation against Toxoplasma infection causes loss of func-
tion in organs as seen in the autoimmune syndrome (Carter,
2013).
DIAGNOSIS OF MATERNAL CONGENITAL TOXOPLASMOSIS
Maternal Toxoplasma infection as a serious risk factor for the fetus
requires accurate and urgent diagnosis for possible prevention and
treatments. Maternal congenital toxoplasmosis is commonly diag-
nosed with utilizing repeated serological tests to assess the types
and the levels of anti-Toxoplasma antibodies. Pregnant moms
are required to be tested in Austria, France, Italy, Portugal, and
Uruguay for antibody detections, but a limited screening pro-
gram is used in Belgium, Germany, and Switzerland. Congenital
and neonatal screening for toxoplasmosis is performed in over
two million women and their babies each year in Europe, North
and South America with estimated cost of over 500 million dol-
lars (Petersen and Schmidt, 2003). While, the United States does
not require routine screening, it is recommended that infants
with serious systemic complications to be tested for toxoplasmo-
sis (Armstrong et al., 2004). In addition, seronegative pregnant
women indicating no previous exposure to infection are at risk
for the infection and recommended to be serology tested monthly
until the labor.
Diagnosis of toxoplasmosis is based on the presence of IgM
and IgG anti-Toxoplasma antibodies, and molecular techniques to
detect organisms (Teixeira et al., 2013). Acute infection is associ-
ated with high levels of anti-Toxoplasma IgM antibody followed
by a rise in IgG levels in 1–3 weeks. Detection of IgM or elevation
of IgG anti-Toxoplasma antibodies suggests acute or reactivation
with a possible transmission of infection to the fetus. An amniotic
fluid test is required to confirm fetal health status and possible
exposure to the maternal infection.
Sabin-Feldman dye test “the international gold standard” is a
complement-lysis-based assay and relatively sensitive and specific
for anti-Toxoplasma IgG antibody. The test is considered more reli-
able than available ELISA kits, but requires live organisms treated
with each diluted serum analyzed under the microscope (Dando
et al., 2001).
In infants with neurological disorders, anti-Toxoplasma IgM
and IgA antibodies plus cerebrospinal fluid PCR to detect Tox-
oplasma DNA are considered to provide a high sensitivity for
diagnosis of congenital toxoplasmosis (Olariu et al., 2014). CSF-
PCR was positive in 47% of about 60 infants from infected moms,
while 0% positive in uninfected healthy ones.
Additionally, western blot analysis is used to detect IgM and
IgA (di Carlo et al., 2011) and RT-PCR for DNA in amniotic fluid
with 98% sensitivity and 100% specificity (Teixeira et al., 2013).
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α-FETOPROTEIN SERUM ANALYSIS
α-Fetoprotein, released by embryonic hepatic cells, is a biomarker
to predict development and birth defects, and useful in prediction
of fetoplacental health and growth progression. Altered levels of
maternal α-fetoprotein are associated with pregnancy, hepatic
complications, tumors, fetal demise, and resorption (Mizejewski,
2007) and may be found useful in prediction of immune responses
and intrauterine death in toxoplasmosis (Kaur and Verma, 1995;
Oz, 2014).
CURRENTLY AVAILABLE AND NOVEL ANTI-TOXOPLASMOSIS
THERAPIES IN HORIZON
Toxoplasmosis is a forgotten disease with no safe and effective ther-
apy available for chronic persistent or pernicious fetal–maternal
infection. Spiramycin has been used in feto-maternal toxoplas-
mosis prevention and treatment in Canada, Latin America, and
Europe for decades but is classified under “experimental therapy”
in the United States. Spiramycin monotherapy is effective in early
pregnancy as a preventive measure but not after fetal exposure
to the infection. In a prospective cohort trial in Brazil, 58% of
newborns from spiramycin-treated moms, in contrast to over 73%
from untreated ones had congenital infection (Avelino et al., 2014).
More than 50% of patients treated with spiramycin retained Tox-
oplasma DNA in peripheral blood and remained infected (Habib,
2008). In another clinical trial of the neonates from infected
moms treated with spiramycin and pyrimethamine plus sulfa-
doxine in France, 24% of 257 children were diagnosed with
congenital infection. Of these, 7% were predicted to be infected in
the first, 24% in the second, and 59% in the third trimesters,
respectively (Bessières et al., 2009). Other fetal–maternal treat-
ments are azithromycin, clarithromycin, atovaquone, dapsone,
and cotrimoxazole (trimethoprim–sulfamethoxazole), however,
their efficacy has not been proven (Petersen and Schmidt, 2003).
ATOVAQUONE AND MATERNAL CONGENITAL
Atovaquone, a hydroxy-1,4-naphthoquinone and FDA approved,
is fairly safe and effective treatment against tachyzoites
and cyst forms of Toxoplasma and anti-Plasmodial (Hudson
et al., 1991; Dunay et al., 2004). It is used in adults, yet
not approved for fetal–maternal and children toxoplasmosis
(Cortina-Borja et al., 2010). Atovaquone is anti-fungal Pneu-
mocystic pneumonia and anti-Babesia microti, causative of
human blood-borne babesiosis endemic in New England and
North Eastern in the United States (Hughes and Oz, 1995;
Oz and Westlund, 2012). Atovaquone acts by targeting mito-
chondrial respiration and binds to the ubiquinol oxidation on
cytochrome bc1 complex to block and to collapse the membrane
in the organisms (Srivastava and Vaidya, 1999; Freyre et al., 2008).
Atovaquone has a half-life of 1.5–3 days and mainly binds to
plasma proteins (99%) and is excreted into feces (94%) with-
out being metabolized (Rolan et al., 1997). Atovaquone has been
shown to protect against maternal congenital toxoplasmosis and
inflammatory complications in murine model (Oz and Tobin,
2012). Atovaquone was superior than the standard of care with
combined pyrimethamine plus sulfadiazine or pyrimethamine
plus clindamycin therapies against brain inflammatory responses
and the severity of infection in the mice (Dunay et al., 2004).
MATERNAL CONGENITAL TOXOPLASMOSIS AND
DICLAZURIL
Diclazuril [4-chlorophenyl [2,6-dichloro-4-(4,5-dihydro-3H-3,5-
dioxo-1,2,4-triazin-2-yl)phenyl acetonitrile] is related to herbi-
cides and used to protect poultry and livestock against coccidiosis,
induced gastroenteritis, morbidity, and mortality. Toxoplasma
and coccidians are members of the phylogeny Apicomplexan with
a highly conserved region of protochlorophyllide with traces
of plant chloroplast epitope not present in humans and ani-
mals. Apicoplast is an extranuclear DNA organelle containing
transcriptional and translational device in Toxoplasma with spe-
cific enzymes unwinding DNA. It is presumably originated from
eukaryotic Ciliate ancestors and prokaryotic green alga in evolu-
tion (Köhler et al., 1997). Apicoplast has a unique sensitivity to
herbicidal agents with a safe and attractive region for drug discov-
ery and vaccine target in Toxoplasma metabolic pathway, absent in
the humans and animals.
Diclazuril and its related compounds specifically invade and
attach to chloroplast epitope and the D1 protein of the Toxo-
plasma apicoplast without interacting to damage the mammalian
host organs (Hackstein et al., 1995). Additionally, diclazuril can
downregulate expression of serine/threonine protein phosphatase
in merozoites of Eimeria to induce apoptosis with possible mech-
anism of action against Toxoplasma organisms (Zhou et al., 2013;
Oz, 2014).
Diclazuril is a non-toxic agent (Assis et al., 2010) with rapid
absorption following oral administration to reach a constant level
in plasma and cerebrospinal fluid. Recent studies have shown
diclazuril to be well tolerated and effective in murine model for
maternal and congenital toxoplasmosis (Oz and Tobin, 2014).
While atovaquone protects against some aspects of gastroin-
testinal complications in experimental congenital toxoplasmosis
in murine (Oz and Tobin, 2012), diclazuril was superior than
atovaquone in improving anemia, colonic length, and hepatic
complications against maternal toxoplasmosis (Oz and Tobin,
2014). In addition, diclazuril and atovaquone combination ther-
apy is anticipated to exert a unique synergistic effect against
toxoplasmosis. Diclazuril monotherapy or combination with ato-
vaquone therapy may warrant clinical trials in maternal congenital
as well as in ocular and chronic toxoplasmosis. Finally, diclazuril
is anticipated to be used as a novel protective and preventive mea-
sure to eliminate the cycle of Toxoplasma infection in the definitive
host, feline.
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